^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SAA1 overexpression

    i
    Other names: SAA1, Serum Amyloid A1, Tumor Protein P53 Inducible Protein 4, TP53I4
    Entrez ID:
    6288
    Related biomarkers:
    Expression
    Others
    2ms
    SAA1 regulated by S1P/S1PR1 promotes the progression of ESCC via β-catenin activation. (PubMed, Discov Oncol)
    S1P/S1PR1 upregulated SAA1 expression and β-catenin phosphorylation at Ser675 in ESCC cells. In conclusion, SAA1 promotes the progression of ESCC by increasing β-catenin phosphorylation at Ser675, and the S1P/S1PR1 pathway plays an important role in its upstream regulation.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SAA1 (Serum Amyloid A1) • MMP9 (Matrix metallopeptidase 9) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    |
    MYC expression • SAA1 overexpression
    1year
    The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma. (PubMed, BMC Cancer)
    Inhibition of SAAL1 expression could regulate cancer growth via cyclin D1 and Bcl-2. SAAL1 is a promising prognostic biomarker in LAC patients.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
    |
    BCL2 expression • CCND1 expression • SAA1 overexpression • SAAL1 overexpression
    over1year
    A functional role for Serum Amyloid A in the molecular regulation of autophagy in breast cancer. (PubMed, Front Oncol)
    Lastly, SAA1/2 knockout promoted resistance to apoptosis and necrosis through the regulation of autophagy. SAA thus regulates autophagy in breast cancer cells to promote tumorigenesis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • SAA1 (Serum Amyloid A1) • SQSTM1 (Sequestosome 1) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • MCM2 (Minichromosome maintenance complex component 2)
    |
    MAPK1 overexpression • SAA1 overexpression
    over1year
    SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. (PubMed, Aging (Albany NY))
    Lastly, we showed that SAAL1 silencing suppresses both malignant phenotype and expression of PD-L1 in lung cancer A549 cells in vitro. These findings suggest that SAAL1 contributes to tumorigenesis and antitumor immunity mechanisms in different cancer types, and may thus serve as both a prognostic biomarker and potential target for cancer immunotherapy.
    Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
    |
    PD-L1 expression • SAA1 overexpression • SAAL1 overexpression
    over1year
    Identification of SAA1 as a prognostic biomarker associated with immune infiltration in glioblastoma. (PubMed, Autoimmunity)
    The overexpression of SAA1 was associated with poor OS and DFS in GBM, and the expression of the SAA1 gene may affect the infiltration level of immune cells. Therefore, SAA1 could be a promising prognostic biomarker associated with immune infiltration and therapeutic target for GBM.
    Journal
    |
    SAA1 (Serum Amyloid A1)
    |
    SAA1 overexpression
    almost3years
    Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD. (PubMed, Biochem Biophys Res Commun)
    In addition, blocking SAA1 expression in vivo not only inhibited platelet aggregation in the liver tissues of NAFLD mice, but also alleviated the inflammation of fatty liver. In conclusion, our findings identify that HFD-induced hepatic overexpressed SAA1 aggravates fatty liver inflammation by promoting intrahepatic platelet aggregation, these results also imply that SAA1 may serve as a potential target for ameliorating NAFLD.
    Journal • IO biomarker
    |
    SAA1 (Serum Amyloid A1)
    |
    SAA1 overexpression
    almost3years
    High SAA1 Expression Predicts Advanced Tumors in Renal Cancer. (PubMed, Front Oncol)
    Our results suggest that SAA1 may possess the potential to serve as a diagnostic and prognostic biomarker for advanced ccRCC patients. Moreover, targeting SAA1 may represent as a novel therapeutic target for advanced ccRCC patients.
    Journal
    |
    SAA1 (Serum Amyloid A1)
    |
    SAA1 overexpression